Skip to content

Magnetic Resonance Imaging (MRI) Study of the Hippocampus After Infarction in the Territory of the Middle Cerebral Artery

To Observe Delayed Neuronal Death of Hippocampus After Middle Cerebral Artery Infarction Through Magnetic Resonance Imaging(MRI) Volume Measurement and Magnetic Resonance Spectroscopy(MRS) Study of Hippocampus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00867581
Enrollment
80
Registered
2009-03-24
Start date
2008-09-30
Completion date
Unknown
Last updated
2009-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

middle cerebral artery, infarction, chronic stage, hippocampal volume, MRI, MRS, neuropsychologic assessment

Brief summary

The purpose of this study is to observe delayed neuronal death of hippocampus after middle cerebral artery infarction in human beings.

Detailed description

40 patients with middle cerebral artery infarction and 40 healthy volunteers will be observed. All of them will receive MRI scan and the assessment of the neuropsychological function (MMSE, AVLT, HAMD) intending to observe delayed neuronal death of hippocampus after middle cerebral artery infarction in human beings.

Interventions

None listed

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of middle cerebral artery infarction * At least six months from the stroke * Must be able to measure his(her) neuropsychologic function (by MMSE, AVLT)

Exclusion criteria

* Unable to undergo examinations due to disturbances of consciousness or medical conditions * Severe dementia, apraxia, disturbances of sensation or perception * Serious complications including severe heart failure, hepatic dysfunction, renal insufficiency,or shock * Parkinson's disease, malignant tumor, autoimmune diseases

Countries

China

Contacts

Primary ContactWei Wang, Doctor
wwang_tjh@126.com86-027-8366-3648

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026